HRP20171895T1 - Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline - Google Patents
Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline Download PDFInfo
- Publication number
- HRP20171895T1 HRP20171895T1 HRP20171895TT HRP20171895T HRP20171895T1 HR P20171895 T1 HRP20171895 T1 HR P20171895T1 HR P20171895T T HRP20171895T T HR P20171895TT HR P20171895 T HRP20171895 T HR P20171895T HR P20171895 T1 HRP20171895 T1 HR P20171895T1
- Authority
- HR
- Croatia
- Prior art keywords
- hemisulfate salt
- expressed
- pharmaceutical preparation
- salt according
- methylene
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 15
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 title claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 230000005855 radiation Effects 0.000 claims 4
- 238000005079 FT-Raman Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 238000001069 Raman spectroscopy Methods 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- -1 lyophilisates Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
- C07D475/14—Benz [g] pteridines, e.g. riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Claims (17)
1. Hemisulfatna sol 5,10-metilen-(6R)-tetrahidrofolne kiseline.
2. Hemisulfatna sol prema zahtjevu 1 naznačena time da je uglavnom u kristalnom obliku.
3. Hemisulfatna sol prema zahtjevima 1 ili 2 naznačena time da ima barem 80%, poželjno 90 %, poželjno 95%, poželjnije 97%, najpoželjnije 99% ili više čistoće kristala.
4. Hemisulfatna sol prema bilo kojem prethodnom zahtjevu naznačena time da ima barem 80%, poželjno 90 %, poželjno 95%, poželjnije 97%, najpoželjnije 99% ili više kemijske čistoće.
5. Hemisulfatna sol prema bilo kojem prethodnom zahtjevu naznačena time da je u bezvodnom obliku.
6. Hemisulfatna sol prema bilo kojem prethodnom zahtjevu naznačena time da ima jedan ili više maksimalnih položaja uzoraka X-zračenja kod kuta difrakcije 2 theta od 4.7°, 17.9°, i 23.3° izraženo u 2θ ±0.2° 2θ (CuKα zračenje, refleksija).
7. Hemisulfatna sol prema bilo kojem prethodnom zahtjevu naznačena time da ima jedan ili više maksimalnih položaja uzoraka X-zračenja kod kuta difrakcije 2theta od 4.7°, 16.6°, 17.9°, 18.4°, 18.9°, 20.2°, 23.3°, 23.5°, 24.3°i 24.7° izraženo u 2θ ±0.2° 2θ (CuKα zračenje, refleksija).
8. Hemisulfatna sol prema bilo kojem prethodnom zahtjevu naznačena time da ima FT-Ramanov spektar koji sadrži jedan ili više maksimuma kod valnih brojeva (izraženo u ±2 cm-1) od 1672, 1656, 1603, 1553, 1474, 1301, 637, 624 i 363.
9. Hemisulfatna sol prema bilo kojem prethodnom zahtjevu naznačena time da ima FT-Ramanov spektar uglavnom u skladu sa slikom 1 i/ili koji ima uzorak rendgenske difrakcije praha (XRPD) uglavnom u skladu sa slikom 2(a) ili 2(b).
10. Hemisulfatna sol prema bilo kojem prethodnom zahtjevu naznačena time da ima barem 2 od slijedećih 10 XRPD maksimuma (izraženo u 2θ ±0.2° 2θ (CuKα zračenje)) at 4.7°, 16.6°, 17.9°, 18.4°, 18.9°, 20.2°, 23.3°, 23.5°, 24.3°i 24.7° i barem 2 od slijedećih 9 FT-Ramanovih maksimuma (izraženo u ±2 cm-1) od 1672, 1656, 1603, 1553, 1474, 1301, 637, 624 i 363.
11. Hemisulfatna sol prema bilo kojem prethodnom zahtjevu naznačena time da ima barem 2 od slijedećih 3 XRPD maksimuma (izraženo u 2θ ± 0.2° 2θ (CuKα zračenje)) at 4.7°, 17.9°, i 23.3° i barem 2 od slijedećih 5 FT-Ramanovih maksimuma (izraženo u ±2 cm-1) od 1672, 1656, 1603, 1553, 1474, 1301, 637, 624 i 363.
12. Farmaceutski pripravak naznačen time da sadrži hemisulfatnu sol 5,10-metilen-(6R)-tetrahidrofolne kiseline prema bilo kojem prethodnom zahtjevu i proizvoljno farmaceutski prihvatljiv nosač.
13. Farmaceutski pripravak prema zahtjevu 12 naznačen time da je u obliku tableta, kapsula, tekućih oralnih pripravaka, prašaka, liofilizata, granula, pastila, rekonstituirajuće praške, injekcijske ili infuzijske otopine ili suspenzija ili supozitorija, poželjno liofilizata.
14. Farmaceutski pripravak prema zahtjevima 12 ili 13 naznačen time da nadalje sadrži barem jedno dodatno terapeutsko sredstvo.
15. Farmaceutski pripravak prema bilo kojem od zahtjeva 12 do 14, naznačen time da je farmaceutski pripravak za oralnu, parenteralnu ili rektalnu primjenu.
16. Hemisulfatna sol 5,10-metilen-(6R)-tetrahidrofolne kiseline prema bilo kojem od zahtjeva 1 do 11 ili farmaceutski pripravak prema bilo kojem od zahtjeva 12 do 15 naznačen time da je za uporabu u terapiji, poželjno za kemoterapiju raka.
17. Spoj prema zahtjevima 1 do 11 naznačen time da je za uporabu u postupku liječenja raka koji obuhvaća davanje hemisulfatne soli 5,10-metilen-(6R)-tetrahidrofolne kiseline prema bilo kojem od zahtjeva 1 do 11 ili farmaceutskog pripravka prema bilo kojem od zahtjeva 12 do 15 subjektu kojem je potreban takav tretman.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13004050.4A EP2837631A1 (en) | 2013-08-14 | 2013-08-14 | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| PCT/EP2014/067447 WO2015022407A1 (en) | 2013-08-14 | 2014-08-14 | Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid |
| EP14758102.9A EP3033344B1 (en) | 2013-08-14 | 2014-08-14 | Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171895T1 true HRP20171895T1 (hr) | 2018-01-26 |
Family
ID=48998397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171895TT HRP20171895T1 (hr) | 2013-08-14 | 2017-12-05 | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline |
| HRP20210743TT HRP20210743T1 (hr) | 2013-08-14 | 2021-05-12 | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210743TT HRP20210743T1 (hr) | 2013-08-14 | 2021-05-12 | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20160185787A1 (hr) |
| EP (3) | EP2837631A1 (hr) |
| JP (5) | JP6617104B2 (hr) |
| KR (2) | KR102410373B1 (hr) |
| CN (2) | CN105452250B (hr) |
| AU (2) | AU2014307872B2 (hr) |
| BR (2) | BR112016002770B1 (hr) |
| CA (1) | CA2921178C (hr) |
| CY (2) | CY1119694T1 (hr) |
| DK (2) | DK3287460T3 (hr) |
| EA (3) | EA032179B1 (hr) |
| ES (2) | ES2871483T3 (hr) |
| HK (2) | HK1217018A1 (hr) |
| HR (2) | HRP20171895T1 (hr) |
| HU (2) | HUE037615T2 (hr) |
| IL (2) | IL244069B (hr) |
| LT (2) | LT3033344T (hr) |
| MX (1) | MX360355B (hr) |
| NO (1) | NO3033344T3 (hr) |
| NZ (2) | NZ745811A (hr) |
| PL (2) | PL3033344T3 (hr) |
| PT (2) | PT3287460T (hr) |
| RS (2) | RS56910B1 (hr) |
| SG (2) | SG11201601016PA (hr) |
| SI (2) | SI3287460T1 (hr) |
| WO (1) | WO2015022407A1 (hr) |
| ZA (1) | ZA201509204B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| US10059710B2 (en) | 2016-02-17 | 2018-08-28 | Merck & Cie | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid |
| EP3446703A1 (en) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| EP3446704A1 (en) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| DK3668516T3 (da) | 2017-08-16 | 2021-12-13 | Merck Patent Gmbh | Stabile lyofilisater omfattende 5,10-methylen-(6r)-tetrahydrofolsyre og en dicarboxylsyre |
| CA3087514A1 (en) * | 2018-01-05 | 2019-07-11 | Isofol Medical Ab | Methods for treating colorectal and metastatic colorectal cancers |
| CN115335740A (zh) * | 2020-03-30 | 2022-11-11 | 住友化学株式会社 | 层叠体 |
| WO2023237483A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid |
| WO2023237480A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Stable pharmaceutical compositions comprising 5,10-methylene-(6r)-tetrahydrofolic acid and nacl |
| WO2023237485A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid |
| WO2023237482A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Concentrated solutions comprising sodium 5,10-methylene-(6r)- tetrahydrofolate |
| WO2023237484A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2300505A (en) * | 1940-10-31 | 1942-11-03 | Bell Telephone Labor Inc | Selective system |
| NZ207354A (en) | 1983-05-20 | 1988-02-29 | Bengt Gustavsson | Device for transferring fluid without the release of droplets |
| DE3821875C1 (hr) * | 1988-06-29 | 1990-02-15 | Eprova Ag, Forschungsinstitut, Schaffhausen, Ch | |
| CH682664A5 (en) * | 1991-10-15 | 1993-10-29 | Eprova Ag | Stable salts of 5,10-methylene tetrahydrofolate. |
| CH684644A5 (de) * | 1992-07-13 | 1994-11-15 | Eprova Ag | 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen. |
| HU226998B1 (en) * | 2000-11-23 | 2010-04-28 | Richter Gedeon Nyrt | Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same |
| CH696628A5 (de) | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
| CH697021A5 (de) | 2003-06-26 | 2008-03-31 | Merck Eprova Ag | Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat. |
| CA2631755A1 (en) | 2005-12-02 | 2007-06-07 | Adventrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate |
| MY148217A (en) * | 2006-12-21 | 2013-03-29 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
| JP5294968B2 (ja) | 2009-05-01 | 2013-09-18 | 三星ダイヤモンド工業株式会社 | スクライブヘッド及び該スクライブヘッドを用いたスクライブ装置 |
| AU2012325801B2 (en) * | 2011-10-19 | 2016-05-12 | Mercator Medsystems, Inc. | Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation |
| EP2837766A1 (de) * | 2013-08-14 | 2015-02-18 | Sika Technology AG | Verfahren zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff sowie System zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff |
| EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| JP6971761B2 (ja) * | 2017-10-11 | 2021-11-24 | 株式会社Ｉｈｉプラント | タンクの構築方法 |
-
2013
- 2013-08-14 EP EP13004050.4A patent/EP2837631A1/en not_active Withdrawn
-
2014
- 2014-08-14 PT PT171902794T patent/PT3287460T/pt unknown
- 2014-08-14 LT LTEP14758102.9T patent/LT3033344T/lt unknown
- 2014-08-14 BR BR112016002770-1A patent/BR112016002770B1/pt active IP Right Grant
- 2014-08-14 US US14/912,328 patent/US20160185787A1/en not_active Abandoned
- 2014-08-14 NZ NZ745811A patent/NZ745811A/en unknown
- 2014-08-14 NZ NZ71782514A patent/NZ717825A/en unknown
- 2014-08-14 CN CN201480044477.8A patent/CN105452250B/zh active Active
- 2014-08-14 PT PT147581029T patent/PT3033344T/pt unknown
- 2014-08-14 EA EA201600172A patent/EA032179B1/ru not_active IP Right Cessation
- 2014-08-14 SI SI201431825T patent/SI3287460T1/sl unknown
- 2014-08-14 AU AU2014307872A patent/AU2014307872B2/en active Active
- 2014-08-14 HU HUE14758102A patent/HUE037615T2/hu unknown
- 2014-08-14 RS RS20171337A patent/RS56910B1/sr unknown
- 2014-08-14 LT LTEP17190279.4T patent/LT3287460T/lt unknown
- 2014-08-14 CN CN201810160334.3A patent/CN108096200A/zh active Pending
- 2014-08-14 PL PL14758102T patent/PL3033344T3/pl unknown
- 2014-08-14 SG SG11201601016PA patent/SG11201601016PA/en unknown
- 2014-08-14 MX MX2016001834A patent/MX360355B/es active IP Right Grant
- 2014-08-14 DK DK17190279.4T patent/DK3287460T3/da active
- 2014-08-14 HU HUE17190279A patent/HUE054504T2/hu unknown
- 2014-08-14 SG SG10201801179VA patent/SG10201801179VA/en unknown
- 2014-08-14 EP EP17190279.4A patent/EP3287460B1/en active Active
- 2014-08-14 EP EP14758102.9A patent/EP3033344B1/en active Active
- 2014-08-14 KR KR1020217009189A patent/KR102410373B1/ko active IP Right Grant
- 2014-08-14 BR BR122020002802-5A patent/BR122020002802B1/pt active IP Right Grant
- 2014-08-14 EA EA202091271A patent/EA202091271A3/ru unknown
- 2014-08-14 KR KR1020167006595A patent/KR102439605B1/ko active IP Right Grant
- 2014-08-14 CA CA2921178A patent/CA2921178C/en active Active
- 2014-08-14 WO PCT/EP2014/067447 patent/WO2015022407A1/en active Application Filing
- 2014-08-14 ES ES17190279T patent/ES2871483T3/es active Active
- 2014-08-14 PL PL17190279T patent/PL3287460T3/pl unknown
- 2014-08-14 RS RS20210630A patent/RS61986B1/sr unknown
- 2014-08-14 JP JP2016533926A patent/JP6617104B2/ja active Active
- 2014-08-14 ES ES14758102.9T patent/ES2654474T3/es active Active
- 2014-08-14 SI SI201430529T patent/SI3033344T1/en unknown
- 2014-08-14 EA EA201892729A patent/EA201892729A1/ru unknown
- 2014-08-14 NO NO14758102A patent/NO3033344T3/no unknown
- 2014-08-14 DK DK14758102.9T patent/DK3033344T3/en active
-
2015
- 2015-12-17 ZA ZA2015/09204A patent/ZA201509204B/en unknown
-
2016
- 2016-02-11 IL IL244069A patent/IL244069B/en active IP Right Grant
- 2016-04-29 HK HK16104972.6A patent/HK1217018A1/zh unknown
-
2017
- 2017-12-05 HR HRP20171895TT patent/HRP20171895T1/hr unknown
- 2017-12-12 CY CY20171101298T patent/CY1119694T1/el unknown
-
2018
- 2018-09-03 JP JP2018164332A patent/JP6735321B2/ja active Active
- 2018-11-29 HK HK18115320.9A patent/HK1256262A1/zh unknown
- 2018-12-06 US US16/212,056 patent/US20190106431A1/en not_active Abandoned
- 2018-12-13 AU AU2018278943A patent/AU2018278943B2/en active Active
-
2019
- 2019-04-02 JP JP2019070293A patent/JP6764501B2/ja active Active
- 2019-09-08 IL IL269170A patent/IL269170B/en active IP Right Grant
-
2020
- 2020-05-11 JP JP2020083208A patent/JP7396960B2/ja active Active
-
2021
- 2021-04-27 CY CY20211100364T patent/CY1124076T1/el unknown
- 2021-05-12 HR HRP20210743TT patent/HRP20210743T1/hr unknown
- 2021-10-08 US US17/496,939 patent/US20220024940A1/en active Pending
- 2021-11-11 JP JP2021183793A patent/JP2022024035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171895T1 (hr) | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline | |
| JP2016528242A5 (hr) | ||
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| LOZYNSKYI et al. | Synthesis and anticancer activity of new thiopyrano [2, 3-d] thiazoles based on cinnamic acid amides | |
| HRP20210149T1 (hr) | Derivati 8-[6-[3-(amino)propoksi]-3-piridil]-1-izopropil-imidazo[4,5-c]kinolin-2-ona kao selektivni modulatori ataxia telangiectasia mutacije (atm) kinaze za liječenje raka | |
| HRP20150771T1 (hr) | Spoj za inhibiciju notch signalnog puta | |
| HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
| PH12016500359A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| RU2018102080A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| HRP20231155T1 (hr) | Modulatori 5'-nukleotidaze, ecto i njihova uporaba | |
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| NZ712180A (en) | Pyridazinone compounds and methods for the treatment of cystic fibrosis | |
| MD4490B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| JP2017519027A5 (hr) | ||
| JP2014527042A5 (hr) | ||
| NZ718487A (en) | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| PH12015502047A1 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| GEP20217286B (en) | Pyridone amides as modulators of sodium channels | |
| MD4575B1 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| WO2018102452A3 (en) | Using substituted pyrazole compounds for treatment of hyperproliferative diseases | |
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения |